Salarius Pharmaceuticals, Inc. amended its merger agreement with Decoy Therapeutics on July 29, 2025, adjusting conversion terms for their preferred stock to facilitate the conversion process for certain note holders. The amendment modifies thresholds for financing triggers and conversion price calculations but keeps the original merger terms intact.